- Zacks•9 hours ago
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports third-quarter earnings results on Oct 27 after market close. Amgen had delivered a positive earnings surprise of 3.65% in the second quarter.
- Zacks•10 hours ago
Amgen Inc. (AMGN) announced that a phase III study on its marketed drug, Xgeva for the prevention of skeletal-related events (SRE) in patients with multiple myeloma met the primary endpoint.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||158.51 x 100|
|Ask||159.50 x 100|
|Day's Range||158.35 - 161.01|
|52wk Range||139.02 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||16.22|
|Avg Vol (3m)||2,774,804|
|Dividend & Yield||4.00 (2.46%)|